Does cXCR4 inhibition in tumor microenvironment facilitate anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice?
Anti-PD-1 treatment can boost antitumor immune responses in HCC models; when used in combination with sorafenib, anti-PD-1 immunotherapy shows efficacy only with concomitant targeting of the hypoxic and immunosuppressive microenvironment with agents such as CXCR4 inhibitors.
This study demonstrates that solifenacin can be beneficial for the management of irritative symptoms after TURBT with subsequent intravesical chemotherapy.